Trellis Bioscience, LLC
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
1
Ending by 2030
Apr 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 15, 2027The maintenance fee for Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling (US 11,725,055) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Binding moieties for biofilm remediation (US 10,570,193) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
- 1 fee due Oct 26, 2027The maintenance fee for Antibodies immunoreactive with heregulin-coupled HER3 (US 9,321,839) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof (US 10,639,370) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,321,839 | Antibodies immunoreactive with heregulin-coupled HER3 In force · From the USPTO record | In force | From the USPTO record | |
| US 10,030,069 | High affinity human antibodies to human cytomegalovirus (CMV) gB protein In force · From the USPTO record | In force | From the USPTO record | |
| US 9,688,744 | High affinity human antibodies to human cytomegalovirus (CMV) GB protein In force · From the USPTO record | In force | From the USPTO record | |
| US 10,676,520 | Antibodies useful in passive influenza immunization In force · From the USPTO record | In force | From the USPTO record | |
| US 10,654,915 | Antibodies useful in passive influenza immunization In force · From the USPTO record | In force | From the USPTO record | |
| US 9,017,668 | High Affinity Human Antibodies to Human Cytomegalovirus (CMV) GB Protein In force · High confidence | In force | High confidence | |
| US 10,233,234 | Binding Moieties for Biofilm Remediation In force · Medium confidence | In force | Medium confidence | |
| US 10,570,193 | Binding moieties for biofilm remediation In force · From the USPTO record | In force | From the USPTO record | |
| US 11,248,040 | Binding moieties for biofilm remediation In force · From the USPTO record | In force | From the USPTO record | |
| US 10,639,370 | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 16: 4 patents in force now held by others · 13 lapsed for an unpaid fee · 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 6 no status recorded